Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 810 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Prognostic Role of Plasmatic BRAF Allele Fraction for Survival in Patients... March 27, 2023 Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 July 6, 2026 When You Lose a Spouse to Cancer and Need Support February 25, 2021 FDA Approves Engineered Cell Therapy for Advanced Synovial Sarcoma August 27, 2024 Load more HOT NEWS Blood test could tailor treatment after surgery Treatment with a Hypomethylating Agent Can Activate or Up-regulate Oncogenes EMA Recommends Granting a Conditional Marketing Authorisation for Epcoritamab Nivolumab Injections Could Make Treatment Easier for More People with Cancer
